These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 9833596

  • 1. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G, Gong PL, Qiu J, Zeng FD, Klotz U.
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [Abstract] [Full Text] [Related]

  • 2. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
    Cai WM, Chen B, Zhou Y, Zhang YD.
    Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
    [Abstract] [Full Text] [Related]

  • 3. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M.
    Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
    [Abstract] [Full Text] [Related]

  • 4. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers.
    Chen X, Zhong D, Blume H.
    Eur J Pharm Sci; 2000 Mar; 10(1):11-6. PubMed ID: 10699379
    [Abstract] [Full Text] [Related]

  • 5. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
    Chen B, Cai WM.
    Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
    [Abstract] [Full Text] [Related]

  • 6. Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
    Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM.
    Circulation; 1989 May; 79(5):1068-76. PubMed ID: 2713973
    [Abstract] [Full Text] [Related]

  • 7. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    Cai WM, Chen B, Cai MH, Chen Y, Zhang YD.
    Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
    [Abstract] [Full Text] [Related]

  • 8. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
    Cai WM, Chen B, Cai MH, Zhang YD.
    Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
    [Abstract] [Full Text] [Related]

  • 9. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E, Müller-Peltzer H, Hollmann M.
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J.
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of propafenone.
    Hii JT, Duff HJ, Burgess ED.
    Clin Pharmacokinet; 1991 Jul; 21(1):1-10. PubMed ID: 1914339
    [Abstract] [Full Text] [Related]

  • 12. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K, Stoschitzky G, Lercher P, Brussee H, Lamprecht G, Lindner W.
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [Abstract] [Full Text] [Related]

  • 13. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K, Lindner W, Schnedl H, Kukovetz WR.
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [Abstract] [Full Text] [Related]

  • 14. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.
    Zhou Q, Yao TW, Yu YN, Zeng S.
    Pharmazie; 2003 Sep; 58(9):651-3. PubMed ID: 14531463
    [Abstract] [Full Text] [Related]

  • 15. Stereoselective metabolism of propafenone by human liver CYP3A4 expressed in transgenic Chinese hamster CHL cells lines.
    Zhou Q, Yao TW, Yu YN, Zeng S.
    Acta Pharmacol Sin; 2001 Oct; 22(10):944-8. PubMed ID: 11749780
    [Abstract] [Full Text] [Related]

  • 16. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W.
    Clin Pharmacol Ther; 1990 Jun; 47(6):740-6. PubMed ID: 2162749
    [Abstract] [Full Text] [Related]

  • 17. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S, Gow R, Verjee Z, Giesbrecht E, Dodo H, Freedom R, Tonn GR, Axelson JE, Zalzstein E, Rosenberg HC, Koren G.
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Concentration-effect relations of 5-hydroxypropafenone in normal subjects.
    Haefeli WE, Vozeh S, Ha HR, Taeschner W, Follath F.
    Am J Cardiol; 1991 May 01; 67(11):1022-6. PubMed ID: 2018005
    [Abstract] [Full Text] [Related]

  • 20. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK, Fischer C, Meese CO, Eichelbaum M.
    Mol Pharmacol; 1991 Jul 01; 40(1):135-42. PubMed ID: 1857335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.